anti-cd47 antibodies & azacitidine for aml and mds
Published 5 years ago • 927 plays • Length 3:34Download video MP4
Download video MP3
Similar videos
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
1:18
the mechanism of action of anti-cd47 antibodies & where these may fit in the mds treatment landscape
-
5:22
magrolimab azacitidine in mds and aml
-
2:38
advances in immunotherapy for mds: anti-tim-3 & anti-cd47 antibodies and small molecule inhibitors
-
2:53
venetoclax and magrolimab for treatment of aml and mds
-
5:36
venetoclax and azacitidine in mds patients
-
6:26
magrolimab with azacitidine in patients with aml
-
2:47
combination therapies with azacitidine for mds
-
12:12
immune checkpoint proteins
-
15:02
hematology myelodysplastic syndrome mds
-
2:17
sirpα/cd47: don’t eat me!
-
0:52
azacitidine in the treatment of mds
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
2:38
azacitidine with checkpoint inhibitors for aml and mds
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
2:26
magrolimab plus azacitidine in treatment-naïve aml
-
3:03
venetoclax and 5-azacytidine for the treatment of mds and cmml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:37
a phase i/ii trial of seclidemstat in combination with azacitidine for patients with mds and cmml
-
1:43
targeting mds stem cells with omacetaxine and azacitidine
-
2:50
magrolimab azacitidine in untreated higher-risk mds
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml